Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin‐like cysteine protease—has been shown to reduce the risk of progression to severe COVID‐19. However, the impact of nirmatrelv...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumagalli, Valeria, Di Lucia, Pietro, Ravà, Micol, Marotta, Davide, Bono, Elisa, Grassi, Stefano, Donnici, Lorena, Cannalire, Rolando, Stefanelli, Irina, Ferraro, Anastasia, Esposito, Francesca, Pariani, Elena, Inverso, Donato, Montesano, Camilla, Delbue, Serena, Perlman, Stanley, Tramontano, Enzo, De Francesco, Raffaele, Summa, Vincenzo, Guidotti, Luca G, Iannacone, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165354/
https://www.ncbi.nlm.nih.gov/pubmed/36946379
http://dx.doi.org/10.15252/emmm.202317580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165354/
https://www.ncbi.nlm.nih.gov/pubmed/36946379
http://dx.doi.org/10.15252/emmm.202317580

Ejemplares similares